Long-term Effect of Gefitinib (ZD1839) on Squamous Cell Carcinoma of the Lung

Anticancer Research

Volumn 24, Issue 1, 2004, Pages 393-396

  Kozuki, Toshiyuki ^a   Kiura, Katsuyuki ^a   Ueoka, Hiroshi ^a   Tabata, Masahiro ^a   Date, Hiroshi ^a   Hamazaki, Shuji ^a   Bessho, Akihiro ^b   Tanimoto, Mitsune ^a  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

EGFR; EGFR TKI; Gefitinib; NSCLC; Squamous; ZD1839

Indexed keywords

CISPLATIN; CYTOKERATIN 19 FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ARTICLE; BLOOD LEVEL; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; CELL PROLIFERATION; CELL SURVIVAL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; LIVER DYSFUNCTION; LOBECTOMY; LONG TERM CARE; LUNG CARCINOMA; LUNG RESECTION; MALE; MEDIASTINUM LYMPH NODE; PRIORITY JOURNAL; RASH; SIDE EFFECT; SIGNAL TRANSDUCTION; SMOKING; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR GROWTH;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HUMANS; KERATINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES; TUMOR MARKERS, BIOLOGICAL;

EID: 1442301615     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, Miller V, Averbuch S, Ochs J, Morris C, Feyereislova A, Swaisland H and Rowinsky EK: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20: 2240-2250, 2002.
2. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP and Baselga J: Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 15: 2237-2246, 2003.
3. Kris MG, Natale RB, Herbst RS, Lynch Jr. TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis C, Albain KS, Brahmer JR, Sandler A, Crawford J, Lutzker SG, Lilenbaum R, Helms L, Wolf M, Averbuch S, Ochs J and Kay A: A phase II trial of ZD1839 ('Iressa') in advanced non-small-cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 21: 292a, 2002. Abstract# 1166.
4. Cohen MH, Chico I and Williams G: NDA 21-399, IRESSA® (gefitinib) Briefing Information. FDA Oncologic Drugs Advisory Committee, September 24, 2002 (http://www.fda.gov/ohrms/dockets/ac/02/briefing/3894b1.htm) Accessed on 8 July 2003.
5. Ruckdeschel JC, Simon G, Antonia S, Haura E, Williams C, Wagner H, Lima CR, Ettienne K, Vaughn J, Bepler G and Lee H: ZD1839 ('Iressa') as a single agent for the treatment of metastatic non-small-cell lung cancer. Proc Am Soc Clin Oncol 21: 318a, 2002. Abstract# 1269.
6. Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B, Hahn R, Tormey DC, Harris J and Comis R: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 7: 1602-1613, 1989.
7. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y and Berille J: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103, 2000.
8. Fujiwara K, Kiura K, Ueoka H, Tabata M, Hamasaki S and Tanimoto M: Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status. Lung Cancer 40: 73-76, 2003.
9. Shah NT, Miller VA, Kris MG, Patel J, Venkatraman E, Benporat L, Zakowski M, Memoli N, Tyson L and Pizzo B: Bronchioalveolar histology and smoking history predict response to gefitinib. Proc Am Soc Clin Oncol 22: 628a, 2003. Abstract# 2524.
10. Shields PG and Harris CC: Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J Clin Oncol 18: 2309-2315, 2000.
11. Kawai H, Kiura K, Tabata M, Yoshino T, Takata I, Hiraki A, Chikamori K, Ueoka H, Tanimoto M and Harada M: Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy. Lung Cancer 35: 305-314, 2002.
12. Katayama H, Tabata M, Kiura K, Hotta K, Kouzuki T, Hisamoto A, Ueoka H and Tanimoto M: Effect of the EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) on EGFR-signaling in a gefitinib-sensitive, non-small-cell lung cancer cell line. Proc Am Ass Cancer Res 44 (2nd ed), 2003. Abstract #3785.
13. Forsythe B and Faulkner K: Clinical experience with gefitinib ('Iressa', ZD1839): an overview of safety and tolerability. Lung Cancer 41(Suppl 2): S70-S71, 2003
14. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T and Nukiwa T: Severe acute interstitial pneumonia and gefitinib. Lancet 361: 137-139, 2003